This is a summary of the European public assessment report (EPAR) for Jentadueto. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Jentadueto.
Therapeutic Indication
### Therapeutic indication Treatment of adult patients with type-2 diabetes mellitus: - Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin. - Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Therapeutic Area (MeSH)
N/AATC Code
A10BD11
ATC Item
metformin and linagliptin
Pharmacotherapeutic Group
Drugs used in diabetes
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Jentadueto
Medicine Name
Jentadueto
Aliases
N/ANo risk management plan link.
